Explore the latest in heart failure, including recent guidelines and advances in treatment of HF with reduced and preserved ejection fraction.
This UK population-based nested case-control study assesses the associations between chronic obstructive pulmonary disease (COPD) medication intensity or stage of airflow limitation and the risk of hospitalization or death in patients with heart failure.
This cohort study uses registry and Medicare claims data to investigate associations between prescription for a renin-angiotensin system (RAS) inhibitor at hospital discharge after transcatheter aortic valve replacement (TAVR) and 1-year all-cause mortality and heart failure readmissions.
This systematic review assessed the evidence suggesting that reduced dietary salt intake benefits patients with heart failure in randomized clinical trials.
This cross-sectional study examines 30-day risk-standardized mortality rates for coronary artery bypass grafting, acute myocardial infarction, and heart failure at top-ranked US News & World Report cardiology vs nonranked hospitals.
This study calculates estimated 5-year number needed to treat values for the primary outcome of cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibitor therapy incremental to angiotensin-converting enzyme inhibitor in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF trial.
This narrative review examines whether angiotensin II receptor blockade coupled with potentiation of key biological signaling pathways can favorably alter the course of heart failure with reduced ejection fraction.
This Editorial argues for the total cessation of clinical trials investigating cardiac stem cells because foundational data has been revealed as fraudulent and previous clinical trials as largely without positive result.
This secondary analysis of a randomized clinical trial assesses if different biomarkers provide information about the risk for all-cause and cause-specific mortality after acute coronary syndrome.
This randomized clinical trial compares the effect of 4 weeks’ administration of inhaled, nebulized inorganic nitrite vs placebo on exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF).
This cohort study uses drug benefit claims data in Ontario, Canada, to estimate the frequency of and variation in prescription nonsteroidal anti-inflammatory drug (NSAID) use among high-risk patients with musculoskeletal disorders and hypertension, heart failure, or chronic kidney disease (CKD) and identifies characteristics associated with prescription NSAID use and its potential association with short-term, safety-related outcomes.
This Patient Page describes candidates for cardiac rehabilitation and how it can help treat cardiovascular disease.
This case-control study investigates whether if the normalized reciprocal of the plasma level of cardiac bridging integrator 1 protein differs in patients with heart failure with preserved ejection fraction, patients with risk factors for heart failure, and individuals with neither heart failure nor risk factors.
This cross-sectional study investigates the association between hospital-level 30-day risk-standardized mortality rates and 30-day risk-standardized payments for acute myocardial infarction (MI), heart failure, and pneumonia among Medicare fee-for-service beneficiaries.
This secondary analysis of the TOPCAT randomized clinical trial examines the association of age, race/ethnicity, obesity, renal function, and atrial fibrillation with levels of natriuretic peptides in heart failure with preserved ejection fraction in people in the Americas.
This study combined secondary analysis of 5 cohorts with murine modeling to assess the association of Bcl2-associated anthanogene 3 (BAG3) genetic variants with outcomes in individuals of African ancestry with dilated cardiomyopathy.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: